XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
   Non-Hodgkin's Lymphoma
   Multiple Myeloma
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Blood Channel
subscribe to Blood newsletter

Latest Research : Cancer : Blood

   DISCUSS   |   EMAIL   |   PRINT
Removing the spleen may help fight leukemia
Jun 2, 2005, 16:05, Reviewed by: Dr.

"For the first time we have been able to provide evidence that the environment around the spleen may play a critical role for patients with leukemia and possibly other types of cancers. When combined with antiangiogenic cancer therapies that work by halting the development of new blood vessels that feed tumor growth, we found that mice experienced prolonged survival."

 
Early surgical removal of the spleen combined with antiangiogenic cancer therapy may halt the progression of leukemia, according to scientists at Sunnybrook and Women's College Health Sciences Centre.

The research, published today in Blood, is the first to show the combination of two factors secreted from the environment of the spleen is important in the promotion of leukemia.

Dr. Yaacov Ben-David, a Senior Scientist in Molecular and Cellular Biology at the Sunnybrook & Women's Research Institute who is the lead investigator in the study and colleagues, including Dr. Yuval Shaked, a post-doctoral fellow, discovered that the spleen of diseased mice provides a supportive environment for cancer cells. The spleen secretes various factors, among them MCP and VEGF, which relate to the immune system and promote formation of new blood vessels. Secretions of these factors cause leukemic cells in the spleen to multiply. In this study, Dr. Ben-David's team showed that these factors might contribute to the progression of breast and other types of cancer.

"For the first time we have been able to provide evidence that the environment around the spleen may play a critical role for patients with leukemia and possibly other types of cancers," says Dr. Ben-David who is also an Associate Professor of Medical Biophysics at the University of Toronto. "When combined with antiangiogenic cancer therapies that work by halting the development of new blood vessels that feed tumor growth, we found that mice experienced prolonged survival."

In the human body, the spleen is located in the upper left side of the abdomen, behind the stomach. Its functions are to filter blood, remove bacteria and make and store blood. Since it is involved in so many bodily functions, it is vulnerable to a wide range of disorders. Any condition that infects the spleen, such as leukemia, can place great strain on the organ and cause it to enlarge. The human body can adapt well to life without this organ, so surgically removing a diseased or damaged spleen is worth further investigation.

Researchers suggest that early surgical intervention by removing the spleen and suppressing the related factors might be considered as a treatment model for human hematological malignancies, cancers of the body's blood-forming and immune systems. Since the research was conducted on mice and does not apply to humans, further research and clinical trials are required before this is practice will be considered as a treatment option in the clinic.
 

- University of Toronto
 

University of Toronto

 
Subscribe to Blood Newsletter
E-mail Address:

 

This research was supported primarily by the Canadian Institutes of Health Research (CIHR) and the National Cancer Institute of Canada (NCIC).

About Sunnybrook and Women's College Health Sciences Centre
Sunnybrook and Women's College Health Sciences Centre is transforming health care through the dedication of its more than 10,000 staff members who provide compassionate and innovative patient focused care. An internationally recognized leader in women's health, academic research and education and an affiliation with the University of Toronto distinguishes Sunnybrook & Women's as one of Canada's premier health sciences centres. Sunnybrook & Women's specializes in caring for newborns, adults and the elderly, treating and preventing cancer, heart problems, neurological and psychiatric conditions, orthopaedic and arthritic conditions and traumatic injuries. Toronto Sunnybrook Regional Cancer Centre is the comprehensive cancer program at Sunnybrook & Women's, a Cancer Care Ontario partner and fully affiliated with the University of Toronto.


Related Blood News

Medication errors affect children's leukemia treatment
JAK-STAT pathway inhibitors are likely to be effective against some leukemias
HO-1 in sickle cell disease
Dasatinib treats resistant cases of CML
HBZ protein enhance ability of HTLV-1 to establish persistent infection
Gene expression signature for Burkitt lymphoma identified
Bcr-Abl mutation and the loss of Arf genes triggers an aggressive form of ALL
New simple and inexpensive test for follow-up of acute lymphoblastic leukemia (ALL)
miRNAs abnormal signalling may lead to platelet-related leukemias
DNA itself can act as a mutagen


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us